Contact Us
Drug Search Results
More Filters [+]

EMB-01

Alternative Names: emb-01, emb01, emb 01
Latest Update: 2024-08-26
Latest Update Note: Clinical Trial Update

Product Description

EMB-01 is a novel bispecific antibody developed based on EpimAbÕs proprietary FIT-Ig¨ platform to simultaneously target EGFR and cMet on tumor cells. The resulting highly potent and durable anti-tumor effect in animal models encouraged EpimAb to rapidly advance EMB-01 to the clinic where it is currently being investigated in oncology indications. (Sourced from: https://www.epimab.com/en/news/11)

Mechanisms of Action: EGFR Inhibitor,C-Met Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai EpimAb Biotherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EMB-01

Countries in Clinic: China, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Carcinoid Tumor|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EMB01X201

P2

Recruiting

Gastrointestinal Cancer|Carcinoid Tumor

2025-12-31

EMB01X101

P2

Recruiting

Non-Small-Cell Lung Cancer

2025-03-14

57%
EMB01X202

P2

Not yet recruiting

Non-Small-Cell Lung Cancer

2024-07-01

57%

Recent News Events

Date

Type

Title

07/01/2023

PubMed

 Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes.

10/21/2022

PubMed

 Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models.

06/07/2022

News Article

 EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

10/11/2021

News Article

 EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu

03/22/2021

News Article

 EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

09/15/2020

News Article

 EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions